Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Go back to Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 86.34 -0.15 (0.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $86.49 | 52 Week High | $8.22 | |||
| Open | $85.87 | 52 Week Low | $3.07 | |||
| Day High | $86.96 | P/E | N/A | |||
| Day Low | $84.20 | EPS | $-1.30 | |||
| Volume | 757,848 | |||||
